




\*Required for saving

## Hemovigilance Module Adverse Reaction Delayed Hemolytic Transfusion Reaction

NHSN Adverse Reaction #: \_\_\_\_\_ \*Facility ID#: \_\_\_\_\_ Patient Information Social Security #: Secondary ID: \_\_\_\_\_ Medicare #: \_\_\_\_\_ Last Name: First Name: Middle Name: ☐ Hispanic or Latino ☐ Not Hispanic or Not Latino **Ethnicity** ☐ Asian ☐ American Indian/Alaska Native ☐ Black or African American Race ☐ Native Hawaiian/Other Pacific Islander ☐ White **\*Blood Group:** □ A- □ A+ □ B- □B+ □ AB- □ AB+ □ O- □ O+ ☐ Blood type not done ☐ Transitional ABO / Rh + ☐ Transitional ABO / Rh - ☐ Transitional ABO / Transitional Rh ☐ Group A/Transitional Rh ☐ Group B/Transitional Rh ☐ Group O/Transitional Rh ☐ Group AB/Transitional Rh **Patient Medical History** List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions) Code: \_\_\_\_\_ Description: Code: \_\_\_\_\_ Description: Code: Description: List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions) Code: Description: Description: Code: \_\_\_\_\_ Description: Code: ☐ UNKNOWN List the patient's comorbid conditions at the time of the transfusion related to the adverse reaction. (Use ICD-10 Diagnostic codes/descriptions) □ NONE Code: \_\_\_\_\_ Description: Code: Description: Description: Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).





	medical procedure including past procedures and procedures to be ent hospital or outpatient stay. (Use ICD-10 Procedure NONE
Code:	Description:
Code:	
Code:	
Transfusion History	
	a previous transfusion?
	☐ WB ☐ RBC ☐ Platelet ☐ Plasma ☐ Cryoprecipitate ☐ Granulocyte
Date of Transfusion:	// UNKNOWN
•	se reaction transfusion-related?
	on about the transfusion adverse reaction.
• •	erse reaction:
_	
	cify
Reaction Details	
	tient was transfused:
Is this reaction associated wi	<u> </u>
investigation Results (C	Only answer questions listed under the selected reaction type.)
*☐ Delayed hemolytic tran	nsfusion reaction (DHTR)
* Delayed hemolytic tran	
* Delayed hemolytic tran Immune Antibody: *Case Definition	nsfusion reaction (DHTR) : Non-immune (specify)
*Delayed hemolytic tran Immune Antibody  *Case Definition Check the following that	nsfusion reaction (DHTR)  : Non-immune (specify)  t occurred between 24 hours and 28 days after cessation of transfusion:
* Delayed hemolytic tran Immune Antibody:  *Case Definition Check the following that Positive direct antigle	t occurred between 24 hours and 28 days after cessation of transfusion:    Document   Description   Description
* Delayed hemolytic tran  Immune Antibody:  *Case Definition Check the following that  Positive direct antigl  Newly-identified red	nsfusion reaction (DHTR)  : Non-immune (specify)  t occurred between 24 hours and 28 days after cessation of transfusion: lobulin test (DAT) blood cell alloantibody in recipient serum
* Delayed hemolytic tran  Immune Antibody:  *Case Definition Check the following that  Positive direct antigl  Newly-identified red	t occurred between 24 hours and 28 days after cessation of transfusion:    Document   Description   Description
* Delayed hemolytic tran  Immune Antibody:  *Case Definition  Check the following that  Positive direct antigle  Newly-identified red  Positive elution test	nsfusion reaction (DHTR)  : Non-immune (specify)  t occurred between 24 hours and 28 days after cessation of transfusion: lobulin test (DAT) blood cell alloantibody in recipient serum
* Delayed hemolytic tran  Immune Antibody:  *Case Definition  Check the following that  Positive direct antigle  Newly-identified red  Positive elution test  Inadequate rise of positive	t occurred between 24 hours and 28 days after cessation of transfusion:    lobulin test (DAT)
* Delayed hemolytic tran  Immune Antibody:  *Case Definition  Check the following that  Positive direct antigle  Newly-identified red  Positive elution test  Inadequate rise of positive	Insfusion reaction (DHTR)    Non-immune (specify)   Institute   Non-immune (specify)
*Delayed hemolytic trar  Immune Antibody:  *Case Definition Check the following that Positive direct antigle Newly-identified red Positive elution test Inadequate rise of positive unexplain	Insfusion reaction (DHTR)    Non-immune (specify)
*Delayed hemolytic trar   Immune Antibody:  *Case Definition Check the following that   Positive direct antigle   Newly-identified red   Positive elution test   Inadequate rise of positive unexplain   Otherwise unexplain   Check all that apply:   Incomplete laborator	Insfusion reaction (DHTR)    Non-immune (specify)
*Delayed hemolytic trar   Immune Antibody:  *Case Definition Check the following that   Positive direct antigle   Newly-identified red   Positive elution test   Inadequate rise of positive unexplain   Otherwise unexplain   Check all that apply:   Incomplete laborator	Instrusion reaction (DHTR)    Non-immune (specify)
* Delayed hemolytic trar  Immune Antibody:  *Case Definition  Check the following that  Positive direct antigle  Newly-identified red  Positive elution test  Inadequate rise of positive unexplain  Check all that apply:  Incomplete laborator  DHTR is suspected,	Instrusion reaction (DHTR)    Non-immune (specify)
* Delayed hemolytic trar  Immune Antibody:  *Case Definition Check the following that Positive direct antigle Newly-identified red Positive elution test Inadequate rise of positive unexplain Check all that apply: Incomplete laborato DHTR is suspected, Other signs and symptoms: (	Insfusion reaction (DHTR)    Non-immune (specify)
*Delayed hemolytic trar  Immune Antibody:  *Case Definition  Check the following that  Positive direct antigle  Newly-identified red  Positive elution test  Inadequate rise of positive unexplain  Check all that apply:  Incomplete laborator  DHTR is suspected,  Other signs and symptoms: ( Generalized:	Insfusion reaction (DHTR)    Non-immune (specify)
* Delayed hemolytic trar  Immune Antibody:  *Case Definition Check the following that Positive direct antigle Newly-identified red Positive elution test Inadequate rise of positive unexplain Check all that apply: Incomplete laborato DHTR is suspected, Other signs and symptoms: ( Generalized: Cardiovascular: Cutaneous:	Insfusion reaction (DHTR)    Non-immune (specify)   Non-immune (specify)
* Delayed hemolytic trar  Immune Antibody:  *Case Definition Check the following that Positive direct antigle Newly-identified red Positive elution test Inadequate rise of positive unexplain Check all that apply: Incomplete laborator DHTR is suspected, Other signs and symptoms: ( Generalized: Cardiovascular:	Insfusion reaction (DHTR)    Non-immune (specify)



Form Approved OMB No. 0920-0666 Exp. Date: 01/31/25 www.cdc.gov/nhsn

Renal:	☐ Hematuria	☐ Hemoglob	inuria [	Oliguria		
Respiratory:	☐ Bilateral infiltrates on chest x-ray ☐ Bronchospasm ☐ Cough					
respiratory.	☐ Hypoxemia					
Other: (specify)						
*Severity						
Did the patient receive or e	experience any of the foll	owing?				
☐ No treatment requi	red	☐ Symptomatic t	reatment only		ì	
☐ Hospitalization, inlo	cuding prolonged hospita	ılization	☐ Life-threa	tening reaction		
☐ Disability and/or inc	capacitation	☐ Congenital and	omaly or birth de	fect(s) of the fetus		
Other medically im	portant conditions	☐ Death	☐ Unknown	or not stated		
*Imputability						
Which best describes the re	elationship between the	transfusion and th	e reaction?			
	for symptoms or newly-i					
	tion for symptoms or new	/ly-identified antibo	ody is present, b	ut transfusion is the mo	st	
likely cause.	or symptoms or newly-ide	entified antibody a	re more likely, hi	it transfileion cannot be	_	
ruled out.	1 symptoms of newly-lac	Titilica artibody al	re more likely, be	at transitistion carriot be	,	
☐ Evidence is clearly in	favor of a cause other th	nan the transfusior	n, but transfusior	n cannot be excluded.		
☐ There is conclusive e	vidence beyond reasona	ble doubt of a cau	ise other than th	e transfusion.		
☐ The relationship betw	een the adverse reaction	n and the transfus	ion is unknown d	or not stated.		
Did the transfusion occur a	t your facility?	S 🗌 NO				
Module-generated DesignOTE: Designations for case		mputability will be	automatically as	signed in the NHSN		
application based on response				eignou in the tyrion		
*Do you agree with the	<u>case definition</u> designa	tion?	☐ YES	□ NO		
^Please indicate your des	ignation					
*Do you agree with the s	severity designation?		☐ YES	□ NO		
^Please indicate your des	ignation					
*Do you agree with the <u>i</u>	mputability designation	n?	☐ YES	□ NO		
^Please indicate your des	ignation					
Patient Treatment						
Did the patient receive treat	ment for the transfusion	reaction?	☐ YES ☐	NO UNKNOWN		
If yes, select treatment(s):						
	he type of medication)		_	_		
☐ Antipyretics		notropes/Vasopres		hodilator	cs	
☐ Intravenous Immunoglobulin ☐ Intravenous steroids ☐ Corticosteroids ☐ Antibiotics						
☐ Antithymocyte	globulin	orin U Othe	er			
☐ Volume resuscitation	n (Intravenous colloids or	crystalloids)				
☐ Respiratory support	(Select the type of suppo	ort)				
☐ Mechanical ve	ntilation	sive ventilation	Oxygen			





☐ Renal replacement therapy <i>(Select the type of therapy)</i> ☐ Hemodialysis ☐ Peritoneal ☐ Continuous Veno-Venous Hemofiltration											
☐ Phlebotomy ☐ Other Specify:											
Outcome											
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined  Date of Death://  ^If recipient died, relationship of transfusion to death:  Definite Probable Possible Doubtful Ruled Out Not determined  Cause of death:  Was an autopsy performed? Yes No											
*Was a particular unit implicated in (i.e., responsible for) the adverse reaction?											
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	(Requ	t number uired for ion and I)	*Unit expiration Date/Time	*Blood group of unit			Implic ated Unit?		
^IMPLICATED	UNIT										
	☐ ISBT-128 ☐ Codabar	☐ Entire unit ☐ Partial unit mL			:	□ A- □B+ □ O-	□ A+ □ AB- □ O+	□ B- □ AB+ □ N/A	Y		
	☐ ISBT-128 ☐ Codabar	☐ Entire unit ☐ Partial unit mL		·———		□ A- □B+ □ O-	□ A+ □ AB- □ O+	□ B- □ AB+ □ N/A	N		
Custom Field	ds										
Label				Label							
Comments											